Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[212Pb]Pb-MP0712 in SCLC and DLL3 Expressing Solid Tumors
NCT07278479Phase 2Recruiting
- Sponsor
- Molecular Partners AG
- Start
- May 2026
- Primary completion
- Sep 2028
- Modality
- Carrier/Scaffold Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MP0712 in small cell lung cancer (SCLC), large cell neuroendocrine carcinoma (LCNEC) and extrapulmonary neuroendocrine carcinoma (EPNEC), sponsored by Molecular Partners AG. Primary endpoints: Incidence and severity of safety events following administration of [212Pb]Pb-DOTAM-MAM279 up to 5 years, Dose modifications of [212Pb]Pb-DOTAM-MAM279 up to 5 years and 2 more. Started May 2026; status: recruiting.
02
Drugs
MP0712
03
Conditions
small cell lung cancer (SCLC)large cell neuroendocrine carcinoma (LCNEC)extrapulmonary neuroendocrine carcinoma (EPNEC)
Beyond the preview
Go deeper on NCT07278479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07278479.